Key facts
- This page summarizes Susan Rodriguez's Form 4 filing for Monopar Therapeutics (MNPR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2026, 17:25.
Susan Rodriguez - 02 Mar 2026 Form 4 Insider Report for Monopar Therapeutics (MNPR)
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2026, 17:25:43 UTC
- Prior SEC filing
- 12 Feb 2026
- Next SEC filing
- 03 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Quan Vu, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Susan Rodriguez filed Form 4 for Monopar Therapeutics (MNPR) on 04 Mar 2026.
Change
- Previous filing in this sequence was filed on 12 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001812511
Primary reporting owner
Rodriguez Susan
- Relationship
- CCSO
- Address
- 1000 SKOKIE BLVD SUITE 350, WILMETTE
- Signature
- /s/ Quan Vu, Attorney-in-fact
- Signature date
- 04 Mar 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MNPR
transaction
Derivative
Stock Options
Award
- Transaction value
- Shares
- +48,728
- Change %
- Price
- $0.000000*
- Shares after
- 48,728
- Date
- 02 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,728
- Exercise price
- $53.47
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Options vest 6/48ths on September 2, 2026 and 1/48th per month thereafter.